RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
04 Aprile 2024 - 10:05PM
(NASDAQ: RXST) – RxSight, Inc., an ophthalmic
medical device company dedicated to providing high-quality
customized vision to patients following cataract surgery, today
announced the commercial launch of its newest Light Adjustable
Lens, the LAL+. The company now offers two lenses in the Light
Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™
(LAL+). The LAL+ has a modified aspheric anterior surface that
creates a small continuous increase in central lens power, which is
designed to slightly extend the depth of focus.
In addition, RxSight’s Light Adjustable Lens system, comprised
of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light
Delivery Device (LDD™) and accessories, will be the subject of
various doctor presentations at the annual meeting of the American
Society of Cataract and Refractive Surgery (ASCRS) in Boston on
April 5-8, 2024.
At this year's ASCRS meeting, the company anticipates more than
20 scientific papers, posters, and presentations on the topic of
the Light Adjustable Lens, including:
Sunday, April 7, 2024
Benefits of Performing Arcuate Incisions with a
Dual-Pulsed Femtosecond Laser on Patients Receiving a Light
Adjustable Lens. Paper presented by Priya M. Mathews, MD
(10:10 a.m. EDT, BCEC, Level 2, 256).
Assessing Binocular Vision Post-Implantation with a
Newly Approved Light Adjustable Lens with a Modified Aspheric
Anterior Surface. Paper presented by T. Hunter Newsom, MD
(1:35 p.m. EDT, BCEC, Level 2, 257B).
Refractive and Visual Outcomes with a Light Adjustable
Lens. Paper presented by Jonathan M. Davidorf, MD (2:15
p.m. EDT, BCEC, Level 2, 257B).
Monday, April 8, 2024
New IOLs to Handle Challenging Cases: LAL.
Presentation by Neda Nikpoor, MD (9:05 a.m. EDT, BCEC, Level 3,
Ballroom East).
A complete listing of accepted posters and papers can be found
on the ASCRS website.
In addition, numerous doctors will present their LAL experience
at the RxSight booth in the convention exhibit hall (Booth 516),
including “The Value of Adjustability,” a panel discussion
featuring Warren Hill, MD, and Yuri McKee, MD. A schedule of these
presentations, which are not affiliated with the official ASCRS
program, is available here and at the company’s booth throughout
ASCRS.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated
to providing high-quality customized vision to patients following
cataract surgery. The RxSight® Light Adjustable Lens system,
comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+™),
RxSight Light Delivery Device (LDD™) and accessories, is the first
and only commercially available intraocular lens (IOL) technology
that can be adjusted after surgery, enabling doctors to customize
and deliver high-quality vision to patients after cataract surgery.
Additional information about RxSight can be found
at www.rxsight.com.
Company Contact:Shelley B. ThunenChief
Financial Officersthunen@rxsight.com
Investor Relations Contact:Oliver MoravcevicVP,
Investor Relationsomoravcevic@rxsight.com
Grafico Azioni RxSight (NASDAQ:RXST)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni RxSight (NASDAQ:RXST)
Storico
Da Set 2023 a Set 2024